With $27B plan to build 4 new plants, Eli Lilly doubles down on US drug manufacturing
At a press conference in Washington, D.C. dubbed “Lilly in America,” the Indianapolis drugmaker said that it will begin construction on four new production facilities in the U.S. The effort will more than double what the company has earmarked for manufacturing since 2020, bringing the total outlay to more than $50 billion.
At a press conference in Washington, D.C. dubbed “Lilly in America,” the Indianapolis drugmaker said that it will begin construction on four new production facilities in the U.S. The effort will more than double what the company has earmarked for manufacturing since 2020, bringing the total outlay to more than $50 billion.
